Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

373.70INR
8:10am BST
Change (% chg)

Rs1.95 (+0.52%)
Prev Close
Rs371.75
Open
Rs373.60
Day's High
Rs378.00
Day's Low
Rs371.10
Volume
404,824
Avg. Vol
2,292,801
52-wk High
Rs515.00
52-wk Low
Rs332.75

Chart for

About

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth... (more)

Overall

Beta: 0.50
Market Cap(Mil.): Rs511,564.19
Shares Outstanding(Mil.): 1,023.74
Dividend: 3.20
Yield (%): 0.96

Financials

  CADI.NS Industry Sector
P/E (TTM): 41.67 30.90 33.64
EPS (TTM): 11.99 -- --
ROI: -- 14.75 14.27
ROE: -- 16.24 15.99

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare Says Zydus Received Final Approval From USFDA For Bumetanide Tablets USP

* SAYS ZYDUS RECEIVED FINAL APPROVAL FROM USFDA FOR BUMETANIDE TABLETS USP Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)

* SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL Source text - https://reut.rs/2r4g6ft Further company coverage:

27 Apr 2018

BRIEF-Cadila Healthcare Says Zydus Gets U.S. FDA Final Nod For Methylprednisolone Tablets USP, Cinacalcet Hydrochloride Tablets

* SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR METHYLPREDNISOLONE TABLETS USP AND CINACALCET HYDROCHLORIDE TABLETS Source text - http://bit.ly/2Hry5Yw Further company coverage:

25 Apr 2018

Earnings vs. Estimates